Have you just developed a new technology that potential partners need to discover? Share it with us and describe how it can be used to further research, drug development, and/or innovation.
Our company Rapid Novor is developing a non-invasive, blood-based test for the multiple myeloma patients’ Minimal Residual Disease (MRD) assessment and monitoring. We use the mass spectrometry based next generation de novo sequencing technology to identify, detect and quantify the M-protein in patient’s serum.
As a world leader in antibody/protein sequencing technology, our company is using the most powerful bioinformatics software developed in-house and optimal experiment design to develop the world most sensitive and non-invasive MRD test to meet an increasingly unmet medical need in multiple myeloma patient care.
We are seeking the opportunity to collaborate with multiple myeloma health care givers, KOLs, drug makers, and investors. Our goal is to benefit thousands of MM patients by introducing a less invasive, more sensitive, and more cost-effective test of MRD. The sooner we reach our goal, the better for patients.